

NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE

Single Technology Appraisal

Pembrolizumab for previously treated solid tumours with high microsatellite instability or mismatch repair deficiency [ID4036]

Final Stakeholder List

Consultees	Commentators (no right to submit or appeal)
<p><u>Company</u></p> <ul style="list-style-type: none"> Merck Sharp & Dohme (UK) Limited (Pembrolizumab) <p><u>Patient/carer groups</u></p> <ul style="list-style-type: none"> AMMF – The Cholangiocarcinoma Charity Black Health Agency for Equality Bowel Cancer UK Cancer 52 Cancer Black Care Cancer Equality Endometriosis UK Gene People Genetic Alliance UK Go Girls GIST Cancer UK Guts UK Helen Rollason Cancer Charity Independent Cancer Patients Voice Macmillan Cancer Support Maggie’s Centres Marie Curie Peaches Womb Cancer Trust Pelican Cancer Foundation South Asian Health Foundation Specialised Healthcare Alliance Tenovus Cancer Care <p><u>Healthcare professional groups</u></p> <ul style="list-style-type: none"> Association of Anaesthetists Association of Cancer Physicians Association of Genetic Nurses & Counsellors Association of Surgeons of Great 	<p><u>General</u></p> <ul style="list-style-type: none"> All Wales Therapeutics and Toxicology Centre Allied Health Professionals Federation Board of Community Health Councils in Wales British National Formulary Cell and Gene Therapy Catapult Department of Health, Social Services and Public Safety for Northern Ireland Healthcare Improvement Scotland Medicines and Healthcare products Regulatory Agency National Association of Primary Care National Pharmacy Association NHS Confederation Scottish Medicines Consortium Welsh Health Specialised Services Committee <p><u>Comparator companies</u></p> <ul style="list-style-type: none"> Accord Healthcare Limited (carboplatin, doxorubicin, fluorouracil, irinotecan, paclitaxel) Accord-UK-Ltd (irinotecan) Almirall Limited (fluorouracil) Bausch & Lomb U.K (megestrol) Baxter Healthcare (doxorubicin) Bristol Myers Squibb Pharmaceuticals (nivolumab, paclitaxel, ipilimumab) Glaxo Smith Kline UK (dostarlimab) Hospira UK Ltd (carboplatin, fluorouracil, irinotecan, raltitrexed, paclitaxel) Inceptua (paclitaxel)

Provisional stakeholder list for the evaluation of pembrolizumab for previously treated solid tumours with high microsatellite instability or mismatch repair deficiency [ID4036]
Issue date: November 2022

Consultees	Commentators (no right to submit or appeal)
<p>Britain and Ireland</p> <ul style="list-style-type: none"> • British Association of Surgical Oncology • British Geriatrics Society • British Institute of Radiology • British Psychosocial Oncology Society • British Society for Gene and Cell Therapy • British Society for Genetic Medicine • British Society for Human Genetics • Cancer Research UK • Royal College of Anaesthetists • Royal College of General Practitioners • Royal College of Nursing • Royal College of Pathologists • Royal College of Physicians • Royal College of Surgeons of England • Royal Pharmaceutical Society • Royal Society of Medicine • Society of Radiographers • UK Clinical Pharmacy Association • UK Oncology Nursing Society <p><u>Others</u></p> <ul style="list-style-type: none"> • Department of Health and Social Care • NHS England • Welsh Government 	<ul style="list-style-type: none"> • Medac GmbH (doxorubicin, fluorouracil, folinic acid, irinotecan) • Mylan (fluorouracil) • Orion Pharma (medroxyprogesterone acetate) • Pfizer Limited (doxorubicin, irinotecan, medroxyprogesterone acetate) • Seacross Pharmaceuticals Ltd (doxorubicin, irinotecan, paclitaxel) • Servier Laboratories Limited (irinotecan, trifluridine-tipiracil) • Sun Pharmaceuticals (irinotecan) • Teva UK (paclitaxel) <p><u>Relevant research groups</u></p> <ul style="list-style-type: none"> • Cochrane UK • Genomics England • Institute of Cancer Research • MRC Clinical Trials Unit • National Institute for Health Research • Research Institute for the Care of Older People <p><u>Associated Public Health groups</u></p> <ul style="list-style-type: none"> • Public Health Wales • UK Health Security Agency

NICE is committed to promoting equality, eliminating unlawful discrimination, and fostering good relations between people who share a protected characteristic and those who do not. Please let us know if we have missed any important organisations from the lists in the matrix, and which organisations we should include that have a particular focus on relevant equality issues.

Definitions:

Consultees

Organisations that accept an invitation to participate in the evaluation; the company that markets the technology; national professional organisations; national patient organisations; the Department of Health and Social Care and the Welsh Government and relevant NHS organisations in England.

The company that markets the technology is invited to make an evidence submission, respond to consultations, nominate clinical experts, and has the right to appeal against the Final Draft Guidance (FDG).

All non-company consultees are invited to submit a statement¹, respond to consultations, nominate clinical or patient experts, and have the right to appeal against the Final Draft Guidance (FDG).

Commentators

Organisations that engage in the evaluation process but that are not asked to prepare an evidence submission or statement, are able to respond to consultations and they receive the FDG for information only, without right of appeal. These organisations are: companies that market comparator technologies; Healthcare Improvement Scotland; related research groups where appropriate (for example, the Medical Research Council [MRC], National Cancer Research Institute); other groups (for example, the NHS Confederation, NHS Alliance, and the British National Formulary).

All non-company commentators are invited to nominate clinical or patient experts.

¹ Non-company consultees are invited to submit statements relevant to the group they are representing.